First Clinical Study of the Safety and Blood Levels of a Human Monoclonal Antibody (2217LS) Against Lyme Disease Bacteria in Healthy People

Condition:   Lyme Disease Interventions:   Biological: 2217LS Fully Human Monoclonal Antibody;   Other: Placebo Comparator (0.9% NaCl) Sponsors:   MassBiologics;   Celerion Recruiting

Source: ClinicalTrials.gov - April 28, 2021 Category: Research Source Type: clinical trials